EW Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 27.83% compared to Edwards Lifesciences's net margin of 12.41%. Edwards Lifesciences's return on equity of 50.81% beat Boston Scientific's return on equity of 8.96%.

Edwards Lifesciences has a consensus price target of $79.48, signalling upside risk potential of 12.58%. On the other hand Boston Scientific has an analysts' consensus of $114.78 which suggests that it could grow by 20.75%. Given that Boston Scientific has higher upside potential than Edwards Lifesciences, analysts believe Boston Scientific is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Edwards Lifesciences's net income of $385.6M is lower than Boston Scientific's net income of $566M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.13x while Boston Scientific's PE ratio is 76.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.39x versus 8.43x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 27.83% compared to Edwards Lifesciences's net margin of 28.41%. Edwards Lifesciences's return on equity of 50.81% beat Intuitive Surgical's return on equity of 15.6%.

Edwards Lifesciences has a consensus price target of $79.48, signalling upside risk potential of 12.58%. On the other hand Intuitive Surgical has an analysts' consensus of $614.67 which suggests that it could grow by 28.39%. Given that Intuitive Surgical has higher upside potential than Edwards Lifesciences, analysts believe Intuitive Surgical is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Edwards Lifesciences's net income of $385.6M is lower than Intuitive Surgical's net income of $685.7M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.13x while Intuitive Surgical's PE ratio is 74.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.39x versus 20.75x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 27.83% compared to Edwards Lifesciences's net margin of 12.66%. Edwards Lifesciences's return on equity of 50.81% beat Steris PLC's return on equity of 7.27%.

Edwards Lifesciences has a consensus price target of $79.48, signalling upside risk potential of 12.58%. On the other hand Steris PLC has an analysts' consensus of $250.11 which suggests that it could grow by 12.27%. Given that Edwards Lifesciences has higher upside potential than Steris PLC, analysts believe Edwards Lifesciences is more attractive than Steris PLC.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison Steris PLC has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.657%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 1% to investors and pays a quarterly dividend of $0.57 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Steris PLC pays out 53.03% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than Steris PLC quarterly revenues of $1.4B. Edwards Lifesciences's net income of $385.6M is higher than Steris PLC's net income of $173.5M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.13x while Steris PLC's PE ratio is 47.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.39x versus 4.10x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 27.83% compared to Edwards Lifesciences's net margin of 11.84%. Edwards Lifesciences's return on equity of 50.81% beat Zimmer Biomet Holdings's return on equity of 7.21%.

Edwards Lifesciences has a consensus price target of $79.48, signalling upside risk potential of 12.58%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $122.35 which suggests that it could grow by 25.57%. Given that Zimmer Biomet Holdings has higher upside potential than Edwards Lifesciences, analysts believe Zimmer Biomet Holdings is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.664%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 0.99% to investors and pays a quarterly dividend of $0.24 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. Edwards Lifesciences's net income of $385.6M is higher than Zimmer Biomet Holdings's net income of $239.5M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.13x while Zimmer Biomet Holdings's PE ratio is 21.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.39x versus 2.59x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.